Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

South Korea · Delayed Price · Currency is KRW

5,030.00

+10.00 (0.20%)

Jun 24, 2026, 3:30 PM KST

5.56% (1Y)

Market Cap	120.25B -5.6%
Revenue (ttm)	269.64B +14.0%
Net Income	347.40M -84.9%
EPS	14.54 -84.8%
Shares Out	23.91M
PE Ratio	346.14
Forward PE	n/a
Dividend	50.00 (0.95%)
Ex-Dividend Date	Dec 29, 2025

Volume	61,585
Open	4,970.00
Previous Close	5,020.00
Day's Range	4,800.00 - 5,100.00
52-Week Range	4,755.00 - 9,300.00
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Kyongbo Pharmaceutical

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research an... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1987

Country South Korea

Stock Exchange Korea Stock Exchange

Ticker Symbol 214390

Full Company Profile

Financial Performance

In 2025, Kyongbo Pharmaceutical's revenue was 264.10 billion, an increase of 10.71% compared to the previous year's 238.56 billion. Earnings were 182.29 million, a decrease of -96.07%.

Financial Statements